Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast Cancer

New England Journal of Medicine

Volumn 326, Issue 26, 1992, Pages 1756-1761

  Desforges, Jane F ^a   Mcguire, William L ^b   Clark, Gary M ^b  

^a Department of Medical Oncology ^*

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN; PLASMINOGEN ACTIVATOR; PROGESTERONE RECEPTOR; PROTEIN P53;

AGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CELL CYCLE S PHASE; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

AGED; AXILLA; BREAST NEOPLASMS; FEMALE; HUMAN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026639108     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199206253262607     Document Type: Review

References (36)

1. McGuire WL. Adjuvant therapy of node-negative breast cancer: another point of view. J Natl Cancer Inst 1988; 80: 1075–6.
2. McGuire. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989; 320: 525–7.
3. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 1006–15.
4. Consensus Development Panel. Consensus statement: treatment of early-stage breast cancer. In: Consensus development conference on the treatment of early-stage breast cancer. Journal of the National Cancer Institute monographs. No. 11. Washington, D.C.: Government Printing Office, 1992:1–5. (NIH publication no. 90–3187.)
5. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63: 181–7.
6. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7: 355–66.
7. Rosen. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239–51.
8. Rosner D, Lane WW. Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy. Cancer 1990; 66: 199–205.
9. McGuire WL. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 1988; 6: 1071–2.
10. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987; 56: 637–42.
11. Hedley DW, Rugg CA, Gelber RD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987; 47: 4729–35.
12. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: a proposed classification of DNA histograms in breast cancer. Cancer 1988; 62: 2183–90.
13. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627–33.
14. Hatschek T, Fagerberg G, Stål O, et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 1989; 64: 1074–81.
15. Joensuu H, Toikkanen S, Klemi PJ. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990; 66: 331–40.
16. O'Reilly SM, Camplejohn RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671–4.
17. Sigurdsson H, Baldetorp B, Borg Å, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045–53.
18. Lewis WE. Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients. Cancer 1990; 65: 2315–20.
19. Cornelisse CJ, van de Velde CJH, Caspers RJC, Moolenaar AJ, Hermans J. DNA ploidy and survival in breast cancer patients. Cytometry 1987; 8: 225–34.
20. Lykkesfeldt AE, Balslev I, Christensen IJ, et al. DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. Acta Oncol 1988; 27: 749–56.
21. Muss HB, Kute TE, Case LD, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 1989; 64: 1894–900.
22. Keyhani-Rofagha S, O'Toole RV, Farrar WB, Sickle-Santanello B, De-Cenzo J, Young D. Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 1990; 65: 1577–82.
23. Winchester DJ, Duda RB, August CZ, et al. The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 1990; 125: 886–9.
24. Fisher B, Gunduz N, Costantino J, et al. DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 1991; 68: 1465–75.
25. Clark GM, Mathieu M-C, Owens MA, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992; 10: 428–32.
26. Chen LC, Neubauer A, Kurisu W, et al. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci U S A 1991; 88: 3847–51.
27. Moe RE, Moe KS, Porter P, Gown AM, Ellis G, Tapper D. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers. Am J Surg 1991; 161: 580–3.
28. Rochefort H, Capony F, Garcia M. Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells 1990; 2: 383–8.
29. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen-related protein, cathepsin D, in breast cancer: an immunohistochemical study. Cancer 1990; 65: 265–71.
30. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–14.
31. Spyratos JF, Maudelonde T, Brouillet J-P, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989; 2: 1115–8.
32. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297–302.
33. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83: 154–5.
34. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1–15, 71–85.
35. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117–20.
36. Nayfield SG, Karp JE, Ford LG, Dott FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450–9.